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Activation of the receptor tyrosine kinase ErbB4 leads
to various cellular responses such as proliferation, sur-
vival, differentiation, and chemotaxis. Two pairs of nat-
urally occurring ErbB4 isoforms differing in their jux-
tamembrane (JMa/JMb) and C termini (cyt1/cyt2) have
been described. To examine the role of ErbB4 in neuron
migration, we cloned and stably transfected each of the
four ErbB4 isoforms in ST14A cells (a neural progenitor
cell line derived from the striatum of embryonic day 14
rats) endogenously expressing the other members of the
ErbB family: ErbB1, ErbB2, and ErbB3. Using immuno-
precipitation assays, we showed that the neuregulin-11
(NRG11) stimulus induced ErbB4 tyrosine phosphoryl-
ation and phosphatidylinositol 3-kinase (PI3K) recruit-
ment and activation (as demonstrated by Akt phos-
phorylation) either directly (ErbB4 cyt1 isoform) or in-
directly (ErbB4 cyt2 isoform). We examined the ability
of the four ErbB4 isoforms to induce chemotaxis and cell
proliferation in response to NRG11 stimulation. Using
migration assays, we observed that only ErbB4-express-
ing cells stimulated with NRG11 showed a significant
increase in migration, whereas the growth rate re-
mained unchanged. Additional assays showed that inhi-
bition of PI3K (but not of phospholipase C) dramati-
cally reduced migratory activity. Our data show that
ErbB4 signaling via PI3K activation plays a fundamen-
tal role in controlling NRG11-induced migration.
The ErbB receptor family consists of four receptor tyrosine
kinases named the epidermal growth factor (EGF)1 receptor,
ErbB2, ErbB3, and ErbB4 (reviewed in Ref. 1). Ligand-depend-
ent activation of ErbB receptors results in homo- or het-
erodimerization, which stimulates receptor trans-phosphoryla-
tion on cytoplasmic tyrosine residues, creating binding sites for
adaptor or enzymatic proteins. EGF receptor and ErbB4 ho-
modimers are active kinases in the absence of coreceptors,
whereas ErbB3 (which has little or no intrinsic tyrosine kinase
activity) and ErbB2 (for which no ligand has been identified)
necessitate coreceptor interaction for signal transduction (2).
Thus, whereas ErbB2 and ErbB3 are limited to heterodimer-
ization, the EGF receptor and ErbB4 can be activated by either
homo- or heterodimerization.
An interesting ErbB4 feature (recently reviewed in Ref. 3) is
the existence of isoforms generated by alternative splicing (4).
One isoform pair (5) is characterized by alternative splicing of
exons located in the extracellular juxtamembrane region con-
ferring (JMa), or not (JMb), susceptibility to proteolytic cleav-
age (6) by a member of the ADAM (a disintegrin and metallo-
protease) family, the tumor necrosis factor--converting
enzyme (7). ErbB4 proteolytic cleavage produces a membrane-
associated 80-kDa fragment that can be degraded by protea-
some activity following polyubiquitination (8) or that can be the
substrate for subsequent -secretase cleavage, which releases
the cytoplasmic domain from the membrane and allows, in-
triguingly, nuclear translocation of a fragment (9, 10) that can
act as cotranscriptional activator of the Yes-associated protein
(11, 12).
The other ErbB4 isoform pair (13) is characterized by the
presence (cyt1) or absence (cyt2) of a cytoplasmic exon contain-
ing a docking site for phosphatidylinositol 3-kinase (PI3K). The
existence of these isoforms suggests that potentially four iso-
forms may exist and evoke functional differences. Actually, in
stable NIH3T3 transfectants, it has been shown that the ErbB4
isoform that does not activate PI3K (cyt2) mediates prolifera-
tion, but not survival or chemotaxis, as does cyt1 (13).
ErbB4 ligands belong to two groups: the neuregulins (NRG1–
4), also termed heregulins, and some members of the EGF
family (betacellulin, epiregulin, and HB-EGF). NRG1 and
NRG2 exist in a number of splicing isoforms and recognize also
ErbB3 as a binding site, whereas NRG3 and NRG4 interact,
with lower affinity, only with ErbB4 (1). In most assays, NRG1
with a -type EGF-like domain is 10–100 times more potent
than NRG1 with an -type EGF-like domain. Moreover, exper-
iments performed with mice with targeted mutations showed
that NRG1 is involved in nervous system and cardiac devel-
opment, whereas NRG1 is involved in breast development
(reviewed in Ref. 14).
In the central nervous system, NRG1 is expressed by both
neurons and glia (15–17), and ErbB4 is expressed in various
part of the brain and nervous system (18–22), including the
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retina (23), the hippocampus (24, 25) and, as we (26, 27) and
others (22) have previously shown, the olfactory bulb. Interest-
ingly, cells coming out of the rostral migratory stream of the
subependymal layer as well as isolated cells in the granule cell
layer, possibly migrating cells, strongly express ErbB4, and
ErbB4 immunoreactivity is found in all the periglomerular and
mitral/tufted cells of the olfactory bulb (26, 28). Furthermore,
ErbB4 is preferentially expressed by interneurons that migrate
tangentially from the ventral to the dorsal rat telencephalon
(29). ErbB4 knockout mice exhibit defects in cranial neural
crest migration and cranial nerve segregation in the developing
hindbrain, but die at embryonic day 10.5 because of abnormal
heart development (30, 31). Recently, heart defects were res-
cued in mutant ErbB4 mice by expressing ErbB4 under the
control of a cardiac-specific myosin promoter (32). Rescued
mice display aberrant cranial nerve architecture and an in-
creased number of large interneurons within the cerebellum.
Expression of a dominant-negative ErbB4 construct in primary
cultures of neuronal cells showed an additional ErbB4 require-
ment for cell migration in the developing cerebellum: the phe-
notype described includes defects in the migration of cerebellar
granule cells (expressing NRGs) along radial glial fibers (usu-
ally expressing ErbB4) (33).
All of this evidence concerning a role for ErbB4 in cell mi-
gration in the nervous system prompted us to find a suitable in
vitro model in which to investigate more deeply the involve-
ment of ErbB4 in migration. For this purpose, we chose ST14A,
an ErbB1/ErbB2/ErbB3-expressing cell line derived from em-
bryonic day 14 rat striatal primordia by retroviral transduction
of a temperature-sensitive allele of the SV40 large T antigen
(34). In this model, cell division and expression of nestin persist
at 33 °C, the permissive temperature, whereas at the non-
permissive temperature of 39 °C, cell division ceases, nestin
expression decreases, and microtubule-associated protein-2 ex-
pression increases (35). Unlike cells derived from somatic fu-
sion (36), they contain a normal complement of chromosomes
without contamination from a neuroblastoma cell line. Follow-
ing intracerebral grafting procedures, ST14A cells develop into
a high percentage of microtubule-associated protein-2- and
glial fibrillary acidic protein-positive cells, suggesting that they
behave as multipotent neural progenitors (37). These proper-
ties, together with the stability of their phenotype over several
years since derivation, associated with the feasibility of their
engineering and subcloning, identify them as an appropriate
model for molecular and biochemical investigations of gene
function (38–40).
In this study, we engineered ST14A cells to express ErbB4
and demonstrate that ErbB4 expression is necessary to confer
on neural progenitor cells the ability to respond to NRG11
through migration. This response is shown to be mediated by
PI3K activation either directly or indirectly through ErbB3
heterodimerization.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—All chemicals and reagents were pur-
chased from Sigma unless otherwise stated. COS-7 cells were pur-
chased from and maintained as recommended by American Type Cul-
ture Collection.
The ST14A cell line was derived from primary cells dissociated from
embryonic day 14 rat striatal primordia and conditionally immortalized
by retroviral transduction of the temperature-sensitive variant tsA58/
U19 of the SV40 large T antigen (34). Cells were cultured on dishes (BD
Biosciences) in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 100 units/ml penicillin, 0.1 mg/ml streptomycin, 1 mM
sodium pyruvate, 2 mM L-glutamine, and 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen). Stable transfectants were grown in
medium containing 5 g/ml puromycin (Sigma). Cells were grown as
monolayers at the permissive temperature of 33 °C in a 5% CO2 atmo-
sphere saturated with H2O. Cells were allowed to grow to near conflu-
ence, and adherent cells were harvested by the trypsin/EDTA method.
The EGF-like domain of mouse NRG11 was produced in our labo-
ratory as a His-tag fusion protein in Escherichia coli (41). The PI3K
inhibitor LY294002 was dissolved in dimethyl sulfoxide (20 mM stock
solution) and stored at 20 °C. The phospholipase C inhibitor U73122
was dissolved in chloroform according to the manufacturer’s instruc-
tions to a final concentration of 2 mM, divided in aliquots, lyophilized,
stored at20 °C, and resuspended in dimethyl sulfoxide just before use
to obtain a 2 mM stock solution. In all experiments, control samples
received the same concentration of dimethyl sulfoxide or other vehicle.
Polyclonal anti-ErbB4 (C-18, sc-283) and monoclonal anti-phospho-
tyrosine (PY99) primary antibodies were from Santa Cruz Biotechnol-
ogy. Polyclonal anti-PI3K p85 antibody was from Upstate Biotechnol-
ogy, Inc. Polyclonal anti-phospho-Ser473 Akt and anti-Akt antibodies
were from Cell Signaling. Horseradish peroxidase-linked donkey anti-
rabbit and sheep anti-mouse secondary antibodies were from Amer-
sham Biosciences.
Proliferation Assay—The proliferation assay was performed accord-
ing to the protocol described by Kueng et al. (42). Briefly, cells were
plated in 200 l of DMEM containing 10% FBS at a density of 1000
cells/well in 96-well plates. The following day (t  0), the medium was
replaced with 2% FBS-containing DMEMwith or without 5 nM NRG11
(100 l/well, 8 wells/treatment). For each plate, an 8-well line without
cells was treated as the entire plate and used as a blank in the following
microplate reader analysis. At t  0, a 96-well plate was fixed and used
as a cell growth starting point. Cell growth was subsequently calculated
at 2 (t  48 h), 4 (t  96 h), and 6 (t  144 h) days after the initiation
of treatments. Briefly, the medium was removed, and cells were fixed by
addition of 100 l of 2% glutaraldehyde in phosphate-buffered saline
(PBS). After being shaken (200 cycles/min) for 20 min at room temper-
ature, plates were washed five times by submersion in deionized water
and air-dried for at least 24 h. Plates were then stained by addition of
a solution (100 l/well) containing 0.1% crystal violet dissolved in
freshly prepared 200 mM boric acid (pH 9.0). After being shaken (200
cycles/min) for 20 min at room temperature, plates were washed five
times by submersion in deionized water and air-dried for at least 24 h.
Bound dye was solubilized by addition of 10% acetic acid (100 l/well)
and 5 min of shaking at room temperature. The absorbance of dye
extracts was measured directly in plates using a Microplate Reader
(Bio-Rad) at a wavelength of 590 nm.
Reverse Transcription (RT)-PCR and Cloning of Rat ErbB4
cDNAs—Total RNA was prepared from olfactory bulbs obtained from
one adult Wistar rat (Charles River Laboratories) using the TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions. Total
RNA (1 g) was subsequently reverse-transcribed to cDNA in a total
volume of 25 l using 200 units of reverse transcriptase (U. S. Biochem-
ical Corp.) in 1 buffer (U. S. Biochemical Corp.) with 7.5 M random
exanucleotide primers (Amersham Biosciences), 0.05% Triton X-100,
0.5 mM dNTPs (Amersham Biosciences), 0.1 g/l acetylated bovine
serum albumin (Amersham Biosciences), and 33 units of RNasin (Am-
ersham Biosciences). As a control, an enzyme-less reaction was per-
formed for each sample. PCRs were carried out in a total volume of 50
l containing 5 l of cDNA, enzyme-less reaction sample, or water
(negative controls), 250 nM each 5- and 3-primers (see below), 2.5 units
of PfuTurbo® DNA polymerase (Stratagene), 100 M dNTPs, and 5%
glycerol. The primers used (produced by Sigma) were designed accord-
ing to the GenBankTM/EBI rat ErbB4 sequence (accession number
NM_021687; corresponding to the JMa-cyt1 isoform, herein numbered
considering the start site as 1): primer ErbB4-11 (5-TGCTAGCCAA-
AAATGAAGCTGGCG-3, with the artificial NheI site underlined and
the ATG codon in boldface) and primer ErbB4-4 (5-GTTTCTCCTTCA-
GGTACCCAGATTCC-3) to obtain the amplicons corresponding to nu-
cleotides 7 to 2228 and primer ErbB4-5 (5-GCACAGCACCCAAT-
CAAGCTC-3) and primer ErbB4-6 (5-TACTGGCCTTGGGGTAGAA-
GGAAG-3) to obtain the amplicons corresponding to nucleotides2105
to 4025. Samples were amplified using a simplified touchdown PCR
protocol: denaturation at 95 °C for 5 min; followed by 10 cycles of
denaturation at 95 °C for 30 s, annealing at 66 °C for 30 s, and exten-
sion at 72 °C for 3 min; followed by 30 cycles of denaturation at 95 °C for
30 s, annealing at 57 °C for 30 s, and extension at 72 °C for 3 min. The
extension step of the last cycle was increased to 30 min. PCR products
were separated by electrophoresis on a 0.8% agarose gel, stained with
ethidium bromide, and visualized with UV light. A 1-kb DNA ladder
(Invitrogen) or BenchTop pGEM DNA markers (Promega) was used as
a size marker. PCR products were purified from agarose gel using the
GenEluteTM gel purification kit (Sigma). To obtain the full-length
ErbB4 cDNAs, the previously obtained amplicons (nucleotides 7 to
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2228 and nucleotides 2105 to 4025) were used as templates in the
presence of primers ErbB4-11 and ErbB4-6 in recombinant PCR accord-
ing to the following protocol: denaturation at 95 °C for 5 min, followed
by 30 cycles of denaturation at 95 °C for 30 s, annealing at 63 °C for
30 s, and extension at 72 °C for 8 min. The extension step of the last
cycle was increased to 30 min. PCR products were separated by elec-
trophoresis on a 0.8% agarose gel, purified from agarose gel using the
GenEluteTM gel purification kit, and cloned into the pCR®-BluntII-
TOPO® vector (Invitrogen) using the Zero Blunt® TOPO® PCR cloning
kit (Invitrogen) following the manufacturer’s instructions.
The DNA of 18 single colonies was obtained using the GenEluteTM
plasmid miniprep kit (Sigma). For each clone, the orientation of the
cDNA in the vector (sense or antisense) was detected by restriction
enzyme digestions using EcoRI and BamHI (Amersham Biosciences).
To identify the different ErbB4 isoforms (cyt1/cyt2 and JMa/JMb),
individual sense clones were analyzed by PCR; the juxtamembrane
domain (fragment 1773 to 2019) was amplified with primer ErbB-
4-12 (5-GAAATGTCCAGATGGCCTACAG-3) and primer ErbB4-13
(5-AACGGCAAATGTCAGAGCCATG-3), and the cytoplasmic domain
(fragment 3054 to 3267) was amplified with primer ErbB4-1 (5-T-
GCTGAGGAATATTTGGTCCCCCA-3) and primer ErbB4-2 (5-TCTG-
GTATGGTGCTGGTTGTGGCT-3). PCRs were carried out in a total
volume of 50 l containing 5 l of DNA or water (negative controls), 250
nM each specific primer, 1 unit of RED TaqTM DNA polymerase (Sigma),
100 M dNTPs, and 5% glycerol. Samples were amplified by denatura-
tion at 95 °C for 3 min, followed by 30 cycles of denaturation at 94 °C for
30 s, annealing at 63 °C (JMa/JMb) or 60 °C (cyt1/cyt2) for 30 s, and
extension at 72 °C for 1 min. The extension step of the last cycle was
increased to 20 min. To amplify the glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) cDNA fragment corresponding to nucleotides
544–732 (GenBankTM/EBI accession number M32599), PCRs were
carried out using primer GAPDH1 (5-TGGCATTGTGGAAGGGCTCA-
TTGAC-3) and primer GAPDH2 (5-ATGCCAGTGAGCTTCCCGTTC-
AGC-3); samples were amplified by denaturation at 95 °C for 3 min,
followed by 25 cycles of denaturation at 94 °C for 30 s, annealing at
60 °C for 30 s, and extension at 72 °C for 1 min. PCR products were
separated by electrophoresis on 2% agarose gels. For all PCRs, the
Thermal Cycler GeneAmp® PCR System 2400 (PerkinElmer Life Sci-
ences) was used.
Sequencing of ErbB4 cDNAs—Two cDNA clones (3A and 3G) corre-
sponding to the full-length JMa-cyt1 and JMa-cyt2 isoforms were com-
pletely sequenced on both strands (Genelab Laboratories, Rome, Italy).
A cDNA clone (3E) corresponding to the JMb isoform was sequenced on
both strands in the region between nucleotides 7 and 2196. The
primers used for sequencing were designed according to the Gen-
BankTM/EBI rat ErbB4 sequence (accession number NM_021687).
Expression Vectors—To generate stable cell lines expressing ErbB4
JMa-cyt1 and JMa-cyt2, the cDNAs corresponding to the two sequenced
isoforms were subcloned into the pIRESpuro2 vector (Clontech); NheI-
NotI fragments obtained from pCR®-BluntII-TOPO®-ErbB4 clones
(containing the entire rat ErbB4 cDNAs) were subcloned into the NheI
and NotI sites of pIRESpuro2. To generate stable cell lines expressing
ErbB4 JMb-cyt1 and JMb-cyt2, a Csp45I-HpaI fragment containing the
entire juxtamembrane region was obtained from the JMb-sequenced
clone and used to replace the JMa region in clones pIRESpuro2-ErbB4-
JMa-cyt1 and pIRESpuro2-ErbB4-JMa-cyt2, yielding pIRESpuro2-
ErbB4-JMb-cyt1 and pIRESpuro2-ErbB4-JMb-cyt2, respectively. The
rat ErbB3 expression vectors pcDNA3-B3 (43) and pcDNA3-B3-6F (44),
in which codons corresponding to Tyr1051, Tyr1194, Tyr1219, Tyr1257,
Tyr1273, and Tyr1286 were substituted with phenylalanine codons, were
a generous gift of Dr. John G. Koland (Department of Pharmacology,
University of Iowa, College of Medicine, Iowa City, IA).
Transfections—For stable transfections, growing ST14A cells were
transfected in triplicate with 10 g of DNA for each construct using 20
l of LipofectAMINE and Opti-MEM I (Invitrogen) according to the
manufacturer’s recommendations. DNA was prepared using the
GenEluteTM endotoxin-free plasmid maxiprep kit (Sigma). Cells trans-
fected with the pIRESpuro2 vector alone were generated to be used as
controls. Cells were cultured in DMEM as described above; and 48 h
after transfection, three different doses of puromycin (5, 10, and 20
g/ml) for each construct were added to the three plates. Individual
clones were recovered and screened for their ErbB4 expression level by
Western blotting as described below.
For transient transfections, growing COS-7 cells were transfected
using specific combinations of expression plasmids as indicated. Briefly,
5 g of each plasmid were mixed in 1 ml of PBS and added to 1 ml of
PBS containing 800 g/ml DEAE-dextran. COS-7 cells were washed
twice with 10 ml of PBS, covered with the DNA/DEAE-dextran/PBS
solution, and incubated for 40 min at 37 °C. Then, 10 ml of DMEM
containing 10% FBS and 0.1 mM chloroquine were added to the cells,
and the cells, spontaneously detached after severe resuspension, were
split in two and incubated at 37 °C for 3 h. After removing the medium,
cells were treated for 3 min with DMEM containing 10% FBS and 10%
Me2SO, washed once with DMEM, and finally covered with DMEM
containing 10% FBS. Twenty-four hours after plating, the cells were
washed with PBS and serum-starved in DMEM for an additional 24 h
before NRG11 stimulation.
Immunoprecipitation and Western Blotting—For immunoprecipita-
tion experiments, confluent cells grown on 10-cm dishes were serum-
starved overnight. The following day, 1 mM sodium orthovanadate was
added to both the untreated and treated cells for at least 30 min prior
to addition of 5 nM NRG11. After 10 min of NRG11 stimulation, cells
were rinsed twice with ice-cold PBS containing 1 mM sodium orthovana-
date and lysed for 20 min on ice with 500 l of cold extraction buffer (20
mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 2 mM EGTA, 1 mM
ZnCl2, 10% glycerol, and 1% Triton X-100 supplemented just prior to
use with 50 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmeth-
ylsulfonyl fluoride, and a mixture of protease inhibitors (Roche Applied
Science)). For immunoprecipitations to be assayed for PI3K activity,
cells were lysed with 500 l of cold lysis buffer (25 mMHepes (pH 8), 150
mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 2 mM EGTA, 1 mM ZnCl2, and
10% glycerol supplemented just prior to use with 50 mM NaF, 1 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and the
mixture of protease inhibitors) (45). Lysates were collected with a cell
scraper, placed in microcentrifuge tubes, rocked at 4 °C for 10 min, and
spun at 4 °C for 20 min at 11,000  g to discard cell debris. Protein
concentration was determined using the BCA kit for protein determi-
nation, and lysates (1.5–2 mg) were diluted to equal concentrations
using extraction buffer (1 mg/ml). Agarose-conjugated protein A beads
(50 l; Santa Cruz Biotechnology) pre-washed three times with extrac-
tion buffer were preincubated for 45 min with primary antibody (1
g/mg of protein), and lysates were added and incubated overnight with
constant rotation at 4 °C. As a control, representative samples
(NRG11-treated or not) were incubated with protein A beads without
primary antibody. The next day, immunoprecipitates were spun at 4 °C
for 1 min at 900  g and rinsed four times with ice-cold extraction
buffer. To release immunoprecipitates from the beads, 2 sample
buffer (62.5 mM Tris (pH 6.8), 4% SDS, 480 mM 2-mercaptoethanol, and
40% glycerol) was added, and the proteins were denatured at 100 °C for
5 min. Proteins were resolved by 8% SDS-PAGE, transferred to a
HybondTM C Extra membrane (Amersham Biosciences) following the
manufacturer’s instruction, and blocked for 1 h at 37 °C in 1 TBST
(150 mM NaCl, 10 mM Tris-HCl (pH 7.4), and 0.1% Tween) plus 5%
nonfat milk. The membranes were incubated overnight at 4 °C in pri-
mary antibodies diluted 1:500 in TBST plus 1% nonfat milk. The next
day, they were rinsed four times with TBST for 5 min each at room
temperature and incubated for 1 h at room temperature with horserad-
ish peroxidase-linked anti-rabbit (1:3000) or anti-mouse (1:10,000) sec-
ondary antibody (diluted in TBST plus 1% nonfat milk). Membranes
were rinsed four times with TBST for 5 min each at room temperature,
and specific binding was detected by the enhanced chemiluminescence
ECL system (Amersham Biosciences) using HyperfilmTM (Amersham
Biosciences). In some cases, the membrane was stripped for 30 min at
50 °C in 0.05 M phosphate buffer (pH 6.5), 10 M urea, and 0.1 M 2-mer-
captoethanol, blocked, tested with secondary antibody to verify accu-
rate cleaning, and reprobed with the indicated primary antibodies for
further analysis. The molecular masses of proteins were estimated
relative to the electrophoretic mobility of cotransferred prestained mo-
lecular mass markers (Invitrogen and Bio-Rad).
Total Protein Extraction—Total proteins were extracted by lysing
cells with extraction buffer as described above or by solubilizing cells in
boiling Laemmli buffer (2.5% SDS and 0.125 M Tris-HCl (pH 6.8)),
followed by 5 min of denaturation at 100 °C in 240 mM 2-mercaptoeth-
anol and 18% glycerol. Protein concentration was determined by the
BCA method, and equal amounts of proteins were loaded onto each
lane, separated by SDS-PAGE, transferred to a HybondTM C Extra
membrane, and analyzed as described above. Bands were quantified by
densitometry using the Gel Doc image documentation system (Bio-Rad)
with Quantity One software. Conclusions were drawn after experi-
ments were repeated a minimum of three times.
PI3K Assays—PI3K activity was assayed in the ErbB4 immunopre-
cipitates in the presence of [-32P]ATP (Amersham Biosciences) and
phosphoinositides (Sigma) as described previously (45, 46).
Motility Assay—The wound healing motility assay was used to meas-
ure two-dimensional movement. Cells were grown to confluence in
12-well plates and serum-starved for 24 h, and then a cross-shaped
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wound was made on the monolayers using a sterile 200-l pipette tip.
The cells were rinsed three times with PBS and placed in serum-free
DMEM with or without 5 nM NRG11. To obtain good reproducibility,
in all experiments, the left arm of the cross was photographed. Photos
were taken at the initiation of the experiment (t 0) and 24 h later (t
24 h) using an Olympus IX50 inverted microscope equipped with a Cool
SNAP-Pro CCD camera (Media Cybernetics, Silver Spring, MD); im-
ages were edited with Image Pro-Plus software (Media Cybernetics).
The areas were measured using the measurement program included.
The two-dimensional movement of the cells was quantified by meas-
uring the surface area of the wound at t  0 and comparing it with the
surface area at t  24 h: healing percentage  (1  t24/t0)  100.
Migration Assay—The Transwell migration assay was used to meas-
ure three-dimensional movement. Cells (105) resuspended in 200 l of
DMEM containing 2% FBS were seeded in the upper chamber of a
Transwell (cell culture insert, no. 353097, BD Biosciences) on a porous
transparent polyethylene terephthalate membrane (8.0-m pore size,
1  105 pores/cm2). The lower chamber (a 24-well plate well) was filled
with DMEM containing 2% FBS with or without 5 nM recombinant
NRG11. The 24-well plates containing cell culture inserts were incu-
bated at 33 °C in a 5% CO2 atmosphere saturated with H2O. After 18 h
of incubation, cells attached to the upper side of the membrane were
mechanically removed using a cotton-tipped applicator. Cells that mi-
grated to the lower side of the membrane were rinsed with PBS, fixed
with 2% glutaraldehyde in PBS for 15 min at room temperature,
washed five times with water, stained with 0.1% crystal violet and 20%
methanol for 20 min at room temperature, washed five times with
water, air-dried, and photographed using an Olympus IX50 inverted
microscope equipped with a Cool SNAP-Pro CCD camera; images were
edited with Image Pro-Plus software. Migrated cells (2 mm2 of micro-
scopic field/sample) were counted using the enclosed measurement pro-
gram. Inhibitors (LY294002, U73122, or the same concentration of
dimethyl sulfoxide as a control) were added to both the upper and lower
chambers 30 min prior to addition of NRG11. In each case, the final
concentration represented a 1:200 dilution of stock solutions in Me2SO,
and control cultures were treated with Me2SO at a 1:200 dilution. We
ruled out the possibility that the effect of migration inhibition was due
to decreased viability caused by inhibitor toxicity by treating 1  105
cells (plated in a 24-well plate) for 18 h with the same amounts of
inhibitors used for migration assays.
Statistical Analysis—Results from different experiments (performed
at least three times in duplicate) were averaged and expressed as
means  S.D. One-way analysis of variance was used to compare data
as indicated in the figure legends. Data were graphed using Microsoft
Excel.
RESULTS
ErbB Expression Patterns in ST14A Cells—Previous data
(13) describe functional studies on chemotaxis mediated by
ErbB4 following stable expression of two isoforms (cyt1/cyt2) of
this receptor in fibroblasts (NIH3T3) that endogenously ex-
press only moderate levels of the ErbB2 receptor (47). Being
interested in the mechanisms by which ErbB4 intervenes in
neural cell migration, we expressed the ErbB4 cDNAs in neural
progenitor cells previously derived and conditionally immortal-
ized from embryonic striatum (34). We verified in these cells
the expression of ErbB1, ErbB2, and ErbB3 and the absence of
ErbB4 by RT-PCR (data not shown) and Western blotting (Fig.
1). The three bands corresponding to apparent molecular
masses of 80, 60, and 50 kDa are nonspecific, being recognized
by anti-ErbB4 primary antibody in whole cell protein extracts
from ST14A cells, which do not express ErbB4, as assessed by
RT-PCR performed on parent ST14A cells (data not shown) or
ST14A cells transfected with the pIRESpuro2 vector alone (see
Fig. 3B, vector lane).
Expression of the Four ErbB4 Isoforms in ST14A Cells—The
cDNAs corresponding to the various ErbB4 isoforms produced
by alternative splicing, JMa-cyt1, JMa-cyt2, JMb-cyt1, and
JMb-cyt2 (clones a1, a2, b1, and b2, respectively) (Fig. 2), were
obtained by RT-PCR performed on rat olfactory bulb RNA,
sequenced, and subcloned into the pIRESpuro2 vector, an in-
ternal ribosome entry site-containing vector for bicistronic ex-
pression of ErbB4 and puromycin resistance (see “Experimen-
tal Procedures”). ST14A cells were stably transfected with the
expression vector incorporating the cDNAs corresponding to
the four ErbB4 isoforms and with the parent vector as a con-
trol. Several puromycin-resistant subclones were isolated, and
the presence of exogenous protein was confirmed by Western
blot analysis (data not shown). For further analysis, two posi-
tive clones for each isoform and one control were selected (Fig.
3A). To investigate for possible transcriptional trans-regulation
between different ErbB4 isoforms, each positive clone was an-
alyzed by RT-PCR to detect the known alternative splicing
isoforms (Fig. 3B). Our data show that each subclone expressed
only the isoform we transfected, ruling out trans-regulation
events.
Transfected cells do not show significant morphology varia-
tions. To better characterize the different ErbB4-expressing
clones, growth rate analysis was performed in low serum for
comparison in the presence and absence of NRG11 (data not
shown). At t  18 h, the time used for motility and migration
assays, we did not observe significant differences between dif-
ferent clones and between treated and untreated cells; how-
ever, comparing all clones at t2  48 h and t4  96 h, we
observed that they can be divided into two groups: a lower rate
group, including wild-type ST14A cells and cells expressing
FIG. 1. Wild-type ST14A cells express ErbB1, ErbB2, and
ErbB3, but not ErbB4. Whole cell protein extracts (50 g) from
wild-type (parent) ST14A cells were analyzed by Western blotting (WB)
and ECL for ErbB1 (first lane), ErbB2 (second lane), ErbB3 (third lane),
and ErbB4 (fourth lane) expression. The three bands (fourth lane)
corresponding to apparent molecular masses of 80, 60, and 50 kDa are
nonspecific, being recognized by anti-ErbB4 primary antibody in whole
cell protein extracts from cells not expressing ErbB4. The molecular
mass standards are expressed in kilodaltons.
FIG. 2. Schematic presentation of the four ErbB4 isoforms. Two
pairs of naturally occurring ErbB4 isoforms differing in their jux-
tamembrane (JMa/JMb) and C termini (cyt1/cyt2) have been described:
JMa-cyt1, JMb-cyt1, JMa-cyt2, and JMb-cyt2 (clones a1, b1, a2, and b2,
respectively). One isoform pair is characterized by alternative splicing
of exons located in the extracellular juxtamembrane region, conferring
(JMa) or not (JMb) susceptibility to proteolytic cleavage operated by a
member of the metalloprotease-disintegrin family (ADAM), the tumor
necrosis factor--converting enzyme (TACE) (7). The other ErbB4 iso-
form pair is characterized by the presence (cyt1) or absence (cyt2) of a
cytoplasmic exon containing a docking site for PI3K by Junttila et al.
(4), modified.
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ErbB4 JMb-cyt1 isoforms (b1-7 and b1-15), and a higher rate
group, including the remaining three isoforms.
NRG11 Activates the ErbB4 Receptor—To establish
whether the different isoforms can be activated by treatment
with exogenous NRG11, we performed immunoprecipitation
experiments. Proteins from whole cell lysates of selected se-
rum-starved clones treated or not with recombinant NRG11
were immunoprecipitated using anti-ErbB4 antibody. The im-
munoprecipitates were separated by SDS-PAGE, transferred to
membranes, and probed for phosphotyrosines (Fig. 4B); after
stripping, the membranes were reprobed for ErbB4 (Fig. 4A).
Bands of phosphoproteins at the appropriate molecular masses
were detected: an 180-kDa band (present in all the isoforms)
corresponding to the entire receptor and an 80-kDa band
(present only in the JMa isoforms) derived by proteolytic cleav-
age attributable to tumor necrosis factor--converting enzyme,
a member of the transmembrane ADAM protease family, also
designated ADAM17 (7), which recognizes the JMa isoform, but
not the JMb isoform. Shedding activity releases the ErbB4
ectodomain fragment into the medium and leaves an 80-kDa
fragment, representing the transmembrane and cytoplasmic
domains associated with the cell (48), which is an active tyro-
sine kinase at least in vitro (8). In the b1-7 clone, we observed
an unusual 90-kDa band that did not correspond to the
known proteolytic intracellular fragment and, moreover, did
not seem to be tyrosine-phosphorylated. Our data show that
the amount of phosphorylated ErbB4 (180 kDa) increased
when the receptors were stimulated by NRG11, exhibiting
different intensities among clones, being higher for clones b1,
b2, and a2 and lower for clone a1.
PI3K Co-immunoprecipitates with All ErbB4 Isoforms—Af-
ter a further stripping, the membranes were reprobed for the
p85 subunit of PI3K (Fig. 4C). Interestingly, our results show
that the amount of PI3K associating with ErbB4 increased
when the receptors were stimulated by NRG11 and, intrigu-
ingly, that all the ErbB4 isoforms co-immunoprecipitated with
PI3K. Such interaction with PI3K has been described down-
stream from NRG1 in NIH3T3 cells transfected with ErbB4
cyt1, but not in NIH3T3 transfected with ErbB4 cyt2 (13). The
two isoforms differ by 16 amino acids present only in the
cytoplasmic tail of ErbB4 cyt1, including a sequence that
matches the consensus binding sequence for the p85 subunit of
PI3K (49). NIH3T3 cells analyzed by Kainulainen et al. (13)
expressed one transfected ErbB4 isoform (a1 or a2) and mod-
erate levels of endogenous ErbB2 (47), but not ErbB1 and
ErbB3. In contrast, ST14A cells transfected with one of the four
ErbB4 isoforms (a1, a2, b1, or b2) expressed not only ErbB2,
but also the EGF receptor and ErbB3. ErbB3 is the only mem-
ber of the ErbB family that incorporates multiple PI3K-binding
sites and has been shown to be a major recruiter of PI3K
(50–52). Each of the six YXXM motifs has the potential to
individually bind the PI3K holoenzyme, albeit to a significantly
lower extent than the six YXXM motifs together (44).
As a consequence of NRG11-induced heterodimerization
with ErbB4, ErbB3 could account for ErbB4 cyt2 and PI3K
co-immunoprecipitation. To test this hypothesis, we transiently
expressed, in COS-7 cells endogenously expressing ErbB2, but
not ErbB3 (44), ErbB4 JMb-cyt1 or JMb-cyt2 together with
wild-type ErbB3 or ErbB3-6F, a mutant ErbB3 protein unable
to bind PI3K (44), or the parent vector as a control and exam-
ined the ability of these receptors to associate with PI3K upon
stimulation by NRG11. Immunoprecipitation analysis con-
firmed that, whereas ErbB4 cyt1 could bind PI3K independ-
ently of ErbB3, ErbB4 cyt2 needed wild-type ErbB3 to co-
immunoprecipitate with PI3K (Fig. 5).
All ErbB4 Isoforms Activate PI3K and Akt—By co-immuno-
precipitation analysis, we demonstrated that ErbB4 recruits
PI3K upon NRG11 stimulation. To prove PI3K activation, as
a preliminary test, PI3K activity was analyzed in ErbB4 im-
munoprecipitates by in vitro kinase assays in which the phos-
phatidylinositol 3-phosphate product was resolved by thin
layer chromatography (data not shown). PI3K activity co-im-
munoprecipitated with both the ErbB4 cyt1 and cyt2 isoforms,
although with lower intensity with the cyt2 isoform.
Phosphorylation of Akt provides an excellent indication of
PI3K activation in the cell; phosphorylation at Thr308 and
Ser473 is critical for activation of the protein Ser/Thr kinase
activity of Akt (53). Therefore, to confirm PI3K activation, we
investigated Akt phosphorylation at Ser473 in ST14A cells ex-
pressing either the ErbB4 cyt1 isoform (clones b1-15 and a1-2)
or the ErbB4 cyt2 isoform (clones b2-16 and a2-6) following
NRG11stimulation(Fig.6).WeobservedaverystrongNRG11-
dependent increase in phosphorylation of Akt at Ser473 in cells
expressing ErbB4 cyt1 and cyt2. The very slight phosphoryla-
tion observed in control cells (vector) could be the consequence
of ErbB2-ErbB3 heterodimer activation (44) and demonstrates
that the strong phosphorylation observed in our samples can be
ascribed to ErbB4 activation.
Two-dimensional Motility Assay—Finally, being interested
in studying migration mediated by ErbB4, we performed a first
round of experiments to determine whether NRG11 treat-
ment can modulate motility, defined here as two-dimensional
movement or chemokinesis. We selected as a model the wound
healing assay, in which the repopulation of cells in a cell-free
region (wound) can be examined quantitatively. Stable ErbB4
clones and control cells were grown until they progressively
reached confluence and then serum-starved for 24 h. A cross-
shaped wound was created in the monolayers, and cells were
placed in medium with or without NRG11 and photographed.
Twenty-four hours later, the cross-shaped wound was photo-
graphed in the same region, and the healing percentage was
quantified comparing the wound area at t 0 and t 24 h. Fig.
7 (upper) shows representative digital images of the wounded
region before and after the incubation period; the healing per-
FIG. 3. Stable transfected clones express ErbB4. A, whole cell
protein extracts (50 g) from ST14A cells stably transfected with the
pIRESpuro2 vector alone or expressing each ErbB4 isoform (JMa-
cyt1  clone a1, JMa-cyt2  clone a2, JMb-cyt1  clone b1, and
JMb-cyt2  clone b2; see Fig. 2) were analyzed by Western blotting and
ECL for ErbB4 expression levels. B, the same clones were analyzed by
RT-PCR for ErbB4 and GAPDH as a control using specific primers
designed to detect the cyt1/cyt2 and JMa/JMb isoforms. The MW lane
contains the molecular size standards (BenchTop pGEM DNA mark-
ers). The bands shown correspond to 222 and 179 bp. The predicted
amplicon molecular sizes are as follows: cyt1, 213 bp; cyt2, 165 bp; JMa,
246 bp; JMb, 207 bp; and GAPDH, 188 bp.
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centage was quantified and is displayed graphically (Fig. 7,
lower). Our results show that NRG11 treatment induced a
statistically significant motility increase only in clones express-
ing ErbB4 JMb-cyt1 and JMb-cyt2. We suppose that the wound
(and the consequent absence of contact inhibition) stimulates
motility and proliferation so strongly that the differences be-
tween clones and between treated and untreated samples can-
not be appreciated significantly. Only clone a2-6 showed a
significant increase in motility compared with control cells;
however, it displayed high basal activity observed also in the
Transwell assays discussed below.
ErbB4 Activation Stimulates Cell Invasion in Three-dimen-
sional Migration Assays—To evaluate the ability of stable
transfectants to migrate in a three-dimensional environment,
hence more similar to brain tissues, we assayed Transwell
migration. A preliminary experiment was carried out with
clone b2-16 using NRG11 at 10 pM to 10 nM. Cells were plated
in the upper chamber of a Transwell filter and allowed to
migrate for 18 h in response to NRG11 added to the lower
chamber before being fixed, stained, and counted. Fig. 8 shows
that the number of migrating cells was augmented signifi-
cantly in the presence of increasing amounts of NRG11 from
1 nM, with a peak at 5 nM.
Representative clones for each ErbB4 isoform and a negative
control (cells transfected with empty vector) were plated in the
upper chamber of a Transwell filter and allowed to migrate for
18 h with or without 5 nM NRG11 added to the lower chamber.
Fig. 9 shows that, for each ErbB4 isoform, NRG11 treatment
significantly increased the number of cells that migrated
through the filter for each treated clone compared with the
respective untreated clone and with the treated negative con-
trol (empty vector).
ErbB4-mediated Migration Requires PI3K (but Not Phospho-
lipase C) Activity—Data highlighting the need for PI3K in
ErbB4 (cyt1 isoform)-mediated migration (13) and our results
concerning ErbB4 and PI3K co-immunoprecipitation prompted
us to investigate a possible role of this signal transduction
protein in cell migration. We performed Transwell assays in
the presence of 5 nM NRG11 and increasing amounts of the
PI3K inhibitor LY294002 (1–100 M) (Fig. 10). To exclude a
FIG. 4. NRG11 induces phosphorylation of ErbB4 proteins and PI3K recruitment. Representative clones expressing the four ErbB4
isoforms (JMa-cyt1 clone a1, JMa-cyt2 clone a2, JMb-cyt1 clone b1, and JMb-cyt2 clone b2; see Fig. 2) and a control clone transfected with
the pIRESpuro2 vector (vect) alone were starved for 24 h in the absence of serum, pretreated for 30 min with 1 mM sodium orthovanadate, and
stimulated () or not () with 5 nM NRG11 for 10 min at 33 °C. Whole cell lysates (1.7 mg) were immunoprecipitated with anti-ErbB4 antibody
and analyzed using anti-ErbB4 antibody (A), anti-phosphotyrosine antibody (B), and anti-PI3K p85 subunit antibody (C). In all samples (including
the control clone), anti-ErbB4 antibody recognized a nonspecific band of 60 kDa. In all ErbB4-expressing clones, an 180-kDa band correspond-
ing to the full-length ErbB4 receptor was bound by anti-ErbB4 antibody and, following ligand stimulation, by anti-phosphotyrosine antibody. The
80-kDa cytoplasmic fragment recognized by anti-ErbB4 antibody was present, as expected, only in JMa-expressing clones (a1 and a2). A
nonspecific 90-kDa band (*) was present only in clone b1-7, but it was not phosphorylated at tyrosine (not shown). (For clone a2-6, the untreated
sample contained more protein than the treated sample as assessed by the anti-ErbB4 immunoblotting shown in A).
FIG. 5. ErbB4 cyt2 needs wild-type ErbB3 to associate with
PI3K. COS-7 cells were transiently cotransfected with the pIRESpuro2
vector incorporating the ErbB4 cyt1 or cyt2 isoform and with either the
parent expression vector (pcDNA3) or the vector incorporating wild-
type (WT) ErbB3 or ErbB3-6F cDNA as indicated. Transiently trans-
fected cells (serum-starved for 24 h) were treated for 10 min at 37 °C in
the presence of 5 nM NRG11 and subjected to detergent lysis; cell
lysates were immunoprecipitated (IP) with anti-ErbB4 antibody and
immunoblotted with antibody recognizing the p85 subunit of PI3K.WB,
Western blot.
FIG. 6. NRG11 induces Akt phosphorylation in ErbB4-ex-
pressing cells. Upper, the ability of NRG11 to induce phosphoryla-
tion of Akt at Ser473 in ST14A cells stably expressing ErbB4 cyt1 (clones
b1-15 and a1-2) or ErbB4 cyt2 (clones b2-16 and a2-6) or transfected
with the pIRESpuro2 parent vector was analyzed via immunoblotting.
Cells starved for 24 h were stimulated for 10 min at 33 °C in the
presence () or absence () of 5 nM NRG11 and lysed in boiling
Laemmli buffer. Whole cell lysates were immunoblotted with anti-
phospho-Ser473 Akt antibody (pAKT) and, after membrane stripping,
with anti-total Akt antibody (AKT). Lower, the results from quantita-
tive densitometric analysis show, for each sample, the ratio between
phospho-Akt and total Akt.
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vehicle inhibitory effect, all samples received the same final
concentration of dimethyl sulfoxide. Our data show that, in
ErbB4-expressing cells, increasing amounts of the PI3K inhib-
itor resulted in greater reduction in NRG11-induced migra-
tion. In contrast, when we performed Transwell assays in the
presence of 5 nM NRG11 and increasing amounts of the phos-
pholipase C inhibitor U73122 (0.1–5 M) (data not shown), we
did not observe a significant decrease in NRG11-induced
migration.
DISCUSSION
This is the first work demonstrating that, in immortalized
neural progenitor cells, ErbB4 expression is necessary to me-
diate NRG11-induced migration and that this phenomenon
occurs via a PI3K-mediated mechanism. We began our re-
search prompted by several intriguing studies suggesting that
ErbB4 may be involved in cell migration and, specially, in
neural cell migration. In fact, interneurons tangentially mi-
grating from the ganglionic eminences express ErbB4 (29).
When the glial ErbB4 receptor is blocked, neurons fail to in-
duce radial glial formation, and their migration along radial
glial fibers is impaired (33). ErbB4 knockout mice (genetically
rescued from embryonic lethality) display defects in cranial
neural crest migration and increased numbers of large inter-
neurons within the cerebellum (32).
In our laboratory, long-distance migration and differentia-
tion of neuronal precursors in adult mammalian brain have
been extensively investigated in the paradigm represented by
the subependymal layer-olfactory bulb system (reviewed in Ref.
54). The olfactory bulb, together with the dentate gyrus of the
hippocampus, belongs to those few specific regions of the brain
undergoing constant neurogenesis during adulthood (55).
Newly formed cells of the olfactory bulb are generated from
multipotent stem cells that reside in the subependymal layer of
the lateral ventricles (see Ref. 56 for a review). The progeny of
these stem cells undergo long-distance tangential migration
along the rostral extension (rostral migratory stream) of the
subependymal layer, reaching the main (57) and accessory (58)
olfactory bulb, where they differentiate into the two principal
classes of interneurons, the granule and periglomerular cells.
Intriguingly, cells coming out of the rostral migratory stream of
the subependymal layer, as well as isolated cells in the granule
cell layer, possibly migrating cells, strongly express ErbB4, and
ErbB4 immunoreactivity is found in all the periglomerular and
mitral/tufted cells of the olfactory bulb (26, 28).
Many efforts have been made to solve the ErbB1 signal
transduction mechanism, whereas little is known about ErbB4
receptor signaling. Neuregulin-stimulated ErbB4 receptor
(cyt1 isoform) has been shown to interact with the adaptor
protein Shc (Src homology and collagen domain) and with the
p85 subunit of PI3K (59). In addition, it has been demonstrated
that, in NIH3T3 cells overexpressing ErbB4 (cyt1 isoform),
HB-EGF induces association of PI3K activity with ErbB4 and
is a potent chemotactic factor (60). Moreover, chemotaxis is
inhibited by wortmannin, a PI3K inhibitor, suggesting a pos-
sible role for PI3K in mediating HB-EGF-stimulated
chemotaxis.
A number of studies in several types of cell lines (reviewed in
Ref. 61) showed that, in response to external stimuli, PI3K
activates protein kinase B/Akt, which phosphorylates Raf-1 at
Ser259, inhibiting Raf-1 and the subsequent extracellular sig-
nal-regulated kinase activity (62, 63). This pathway has been
recently confirmed for neuregulin-induced ErbB4 signal trans-
duction (64).
Previous studies suggest that neuregulin (and other growth
factors)-activated PI3K may be involved in actin reorganiza-
tion, formation of lamellipodia, membrane ruffling, and cell
migration (65–68). PI3K cooperates with the small GTPases
Rac and Cdc42 and with p21-activated kinase-1 in the forma-
tion of actin-rich extensions via stimulation of actin polymeri-
zation (66, 69–71). There is also evidence for the association of
PI3K with microtubules (72) and for the involvement of the
microtubule system in the outgrowth of cell processes induced
by PI3K (73, 74).
The aim of our research was to study the role of ErbB4 in
neural cell migration. We began our analysis by seeking a
FIG. 8. NRG11 stimulates migration of ErbB4-expressing
cells. The ability of NRG11 to stimulate chemotaxis of a representa-
tive clone expressing ErbB4 (b2-16) was analyzed by Transwell migra-
tion assay. Cells (105) were plated in the upper chamber of a Transwell
filter and allowed to migrate for 18 h in response to NRG11 added to
the lower chamber (using NRG11 at 10 pM to 10 nM, corresponding to
0.1–100 ng/ml) before being fixed and stained. Cells (2 mm2 of micro-
scopic field/sample) were photographed, and migrated cells were
counted. Data represent means  S.D. *, p  0.05 (stimulated samples
compared with the untreated sample).
FIG. 7.Motility of ErbB4-expressing cells. A cross-shaped wound
was made on serum-starved confluent monolayers of cell clones repre-
sentative of each ErbB4 isoform and the control vector. The cells were
rinsed and placed in medium with () or without () 5 nM NRG11.
Upper, images were taken at the start of the experiment (t  0) and 12
and 24 h later. Clone b1-15 was chosen as a representative. Wound
healing was evaluated as the decrease in the surface area of the wound
at t  24 h. Lower, the percent wound healing was quantified and is
displayed, where healing percentage  (1  t24/t0)  100. Bars repre-
sent means  S.D. Experiments were performed three times in dupli-
cate. *, p  0.05.
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suitable in vitro model, and we identified an embryonic neuro-
epithelial striatal immortalized cell line, ST14A (34), which
lacks ErbB4, but expresses all other members of the ErbB
family. Starting from data describing two different isoform
pairs (5, 13), we cloned the full-length cDNAs encoding the four
potential ErbB4 isoforms (4) and expressed them in our cell
model. We found that NRG11 induced ErbB4 phosphorylation
and co-immunoprecipitation of PI3K with all ErbB4 isoforms.
In addition, we demonstrated that, following NRG11 stimu-
lation, all ErbB4 isoforms activated PI3K and induced Akt
phosphorylation at Ser473, which provides an excellent indica-
tion of PI3K activation in the cell (53).
However, according to a previous study (13), only the ErbB4
cyt1 isoform should interact with PI3K because the cyt2 iso-
form lacks the consensus sequence (49) for the binding of this
signal transduction protein. Nevertheless, the previous model
is different: fibroblasts expressing moderate levels of ErbB2
(47) and stably transfected with an ErbB4 isoform were stud-
ied, whereas we studied a neural progenitor cell line endog-
enously expressing ErbB1, ErbB2, and ErbB3 and one trans-
fected ErbB4 isoform. Therefore, in NIH3T3 fibroblasts, ErbB4
can homodimerize or heterodimerize only with ErbB2. ErbB2
has been described to associate with Src (75, 76), a potential
mediator of PI3K activation (77). Nevertheless, in NIH3T3
cells, it has been shown that cyt2, the ErbB4 isoform that does
not activate PI3K, mediates proliferation, but not survival and
chemotaxis (13), which are mediated by PI3K, suggesting that
ErbB2 cannot account for the PI3K recruitment mediated by
NRG11-stimulated ErbB4.
Intriguingly, there are six PI3K-binding motifs in the C-
terminal domain of ErbB3 (50–52), and one simple explanation
may include direct recruitment of PI3K by the activated ErbB3
receptor. We tested this hypothesis by expressing ErbB4 cyt2
together with wild-type ErbB3 (43) or ErbB3 mutated at the six
tyrosines included in the PI3K-binding motifs (44), and we
demonstrated that the ErbB4 cyt2 isoform could co-immuno-
precipitate with PI3K only when coexpressed with the wild-
type ErbB3 receptor.
Finally, to test our preliminary hypothesis, we performed
migration assays and showed that ErbB4 confers to ST14A
cells the ability to respond to NRG11 through migration. This
ligand is not ErbB4-specific and could activate the ErbB3 re-
ceptor; nevertheless, control cells expressing ErbB3, but lack-
ing ErbB4, failed to migrate, indicating that, in our cell model,
ErbB4 is necessary for this activity. Our data show that every
ErbB4 isoform (endowed or not with the PI3K-binding motif)
mediates NRG11-induced migration, although with different
intensity, and we have demonstrated that PI3K activation is
necessary for ErbB4-mediated migration either directly or in-
directly through ErbB3 heterodimerization.
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FIG. 10. PI3K inhibition decreases NRG11-induced migra-
tion. Representative clones expressing the four ErbB4 isoforms (JMa-
cyt1  clone a1, JMa-cyt2  clone a2, JMb-cyt1  clone b1, and
JMb-cyt2  clone b2; see Fig. 2) were assayed for Transwell migration
in the presence, in both the upper and lower chambers, of increasing
amounts of the PI3K inhibitor LY294002 dissolved in dimethyl sulfox-
ide (DMSO) added 30 min prior to stimulation with 5 nM NRG11. All
samples, except the control (CTR), had the same final concentration of
dimethyl sulfoxide. All samples were stimulated with 5 nM NRG11.
Data represent means  S.D. **, p  0.01; ***, p  0.001 (control and
LY294002 inhibitor-treated samples compared with the untreated sam-
ple (1% Me2SO)).
FIG. 9. ErbB4 is necessary to mediate NRG11-induced migration, and each ErbB4 isoform significantly mediates this activity.
Representative clones expressing the four ErbB4 isoforms (JMa-cyt1  clone a1, JMa-cyt2  clone a2, JMb-cyt1  clone b1, and JMb-cyt2  clone
b2; see Fig. 2) and a control clone transfected with the pIRESpuro2 vector (vect) alone were assayed for Transwell migration. Cells (105) were plated
in the upper chamber of a Transwell filter and allowed to migrate for 18 h in the presence (black bars) or absence (untreated; white bars) of 5 nM
NRG11 added to the lower chamber before being fixed and stained. Cells (2 mm2 of microscopic field/sample) were photographed, and migrated
cells were counted. Data represent means  S.D. from several independent assays. *, p  0.05; **, p  0.01; ***, p  0.001 (upper asterisks, for
each clone, treated samples compared with untreated samples; lower asterisks, for each clone, NRG11-treated samples compared with the
NRG11-treated vector, showing that data for all samples are significant, suggesting that the presence of ErbB4 is necessary to mediate
NRG11-induced migration).
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